Post by account_disabled on Mar 6, 2024 6:39:09 GMT
The Astra Zeneca vaccine and the University of Oxford, the great hope
An experimental vaccine being developed by AstraZeneca and the University of Oxford against the new coronavirus produced an immune response in the early stages of clinical trials, data showed on Monday. This helps preserve hopes of its use by the end of the year.
The vaccine, called AZD1222, has been called by the World Health Organization's chief scientist as the leading candidate in a global race to stop a pandemic that has killed more than 600,000 people .
More than 150 potential vaccines are in various stages of development, and American drugmaker Pfizer and Chinese company CanSino Biologics have also reported positive responses for their candidates.
The vaccine from AstraZeneca and the British Chile Mobile Number List University of Oxford did not cause serious side effects and elicited immune responses from antibodies and T cells , according to trial results published in the medical journal The Lancet . This is the strongest response seen in people who received two doses.
British Prime Minister Boris Johnson, whose government has helped fund the project, called the results "very positive news," although researchers cautioned that the project is still in an early phase.
There is still a lot of work to do before we can confirm whether our vaccine will help manage the COVID-19 pandemic. We still do not know how strong the immune response we must provoke to effectively protect against SARS-CoV-2 infection.
Sarah Catherine Gilbert, professor of vaccinology at the University of Oxford and co-founder of Vaccitech.
Given this, AstraZeneca shares rose 10%, but then gave up most of those gains to close the day at 1.45%.
The global pharmaceutical company has signed agreements with governments around the world to supply the vaccine should it prove effective and win regulatory approval, and has said it will not seek to profit from the vaccine during the pandemic.
The Astra Zeneca vaccine and the University of Oxford, the great hope
AZD1222 was developed by Oxford and licensed to AstraZeneca, which has put it into large-scale, late-stage testing to test its effectiveness. So far, it has signed agreements to produce and supply more than 2 billion doses of the vaccine, with 300 million doses destined for the United States.
Pascal Soriot, AstraZeneca's chief executive, said the company was on track to produce doses by September , but the hope it would be available this year depended on how quickly late-stage testing could be completed, given the decline. of the prevalence of the virus in Great Britain.
Late-stage trials are underway in Brazil and South Africa and are scheduled to begin in the United States, where prevalence is highest.
Goal: two doses
The trial results showed a stronger immune response in 10 people who were given an extra dose of the vaccine after 28 days, echoing a trial in pigs.
Oxford's Gilbert said the early-stage trial was unable to determine whether one or two doses would be needed to provide immunity.
We may not need two doses, but we want to know what we can achieve.
Sarah Catherine Gilbert, professor of vaccinology at the University of Oxford and co-founder of Vaccitech.
AstraZeneca biopharma chief Mene Pangalos said the company was leaning toward a two-dose strategy for late-stage trials, and did not want to risk a single or lower dose that might not work.
The antibody levels generated were “in the region” of those seen in convalescent patients, he said.
The trial included 1,077 healthy adults ages 18 to 55 with no history of COVID-19. Researchers said the vaccine caused minor side effects more often than a control group, but some of them could be reduced by taking the pain reliever paracetamol, also known as acetaminophen.
An experimental vaccine being developed by AstraZeneca and the University of Oxford against the new coronavirus produced an immune response in the early stages of clinical trials, data showed on Monday. This helps preserve hopes of its use by the end of the year.
The vaccine, called AZD1222, has been called by the World Health Organization's chief scientist as the leading candidate in a global race to stop a pandemic that has killed more than 600,000 people .
More than 150 potential vaccines are in various stages of development, and American drugmaker Pfizer and Chinese company CanSino Biologics have also reported positive responses for their candidates.
The vaccine from AstraZeneca and the British Chile Mobile Number List University of Oxford did not cause serious side effects and elicited immune responses from antibodies and T cells , according to trial results published in the medical journal The Lancet . This is the strongest response seen in people who received two doses.
British Prime Minister Boris Johnson, whose government has helped fund the project, called the results "very positive news," although researchers cautioned that the project is still in an early phase.
There is still a lot of work to do before we can confirm whether our vaccine will help manage the COVID-19 pandemic. We still do not know how strong the immune response we must provoke to effectively protect against SARS-CoV-2 infection.
Sarah Catherine Gilbert, professor of vaccinology at the University of Oxford and co-founder of Vaccitech.
Given this, AstraZeneca shares rose 10%, but then gave up most of those gains to close the day at 1.45%.
The global pharmaceutical company has signed agreements with governments around the world to supply the vaccine should it prove effective and win regulatory approval, and has said it will not seek to profit from the vaccine during the pandemic.
The Astra Zeneca vaccine and the University of Oxford, the great hope
AZD1222 was developed by Oxford and licensed to AstraZeneca, which has put it into large-scale, late-stage testing to test its effectiveness. So far, it has signed agreements to produce and supply more than 2 billion doses of the vaccine, with 300 million doses destined for the United States.
Pascal Soriot, AstraZeneca's chief executive, said the company was on track to produce doses by September , but the hope it would be available this year depended on how quickly late-stage testing could be completed, given the decline. of the prevalence of the virus in Great Britain.
Late-stage trials are underway in Brazil and South Africa and are scheduled to begin in the United States, where prevalence is highest.
Goal: two doses
The trial results showed a stronger immune response in 10 people who were given an extra dose of the vaccine after 28 days, echoing a trial in pigs.
Oxford's Gilbert said the early-stage trial was unable to determine whether one or two doses would be needed to provide immunity.
We may not need two doses, but we want to know what we can achieve.
Sarah Catherine Gilbert, professor of vaccinology at the University of Oxford and co-founder of Vaccitech.
AstraZeneca biopharma chief Mene Pangalos said the company was leaning toward a two-dose strategy for late-stage trials, and did not want to risk a single or lower dose that might not work.
The antibody levels generated were “in the region” of those seen in convalescent patients, he said.
The trial included 1,077 healthy adults ages 18 to 55 with no history of COVID-19. Researchers said the vaccine caused minor side effects more often than a control group, but some of them could be reduced by taking the pain reliever paracetamol, also known as acetaminophen.